Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nefazodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefazodone SCHEMBL30054492 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL8195097 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL41119 | 1.00 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL7659683 | 0.99 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL6479060 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL29375893 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL35089 | 0.99 | DRD2 (1.00) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL27748020 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL9275261 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A | |
| Nefazodone SCHEMBL27748022 | 0.98 | DRD2 (0.98) | DRD2HTR2ADRD3SLC6A4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| US-6034085-A | ANTIDEPRESSANTS; QUICK DISSOLVING, ABSORPTION | BRISTOL-MYERS SQUIBB CO. (US) | 2000-03-07 | — | — | US | disclosed |